Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 16;10(7):301.
doi: 10.3390/jcdd10070301.

Investigating the Association between Coronary Artery Disease and the Liver Fibrosis-4 Index in Patients Who Underwent Coronary Computed Tomography Angiography: A Cross-Sectional Study

Affiliations

Investigating the Association between Coronary Artery Disease and the Liver Fibrosis-4 Index in Patients Who Underwent Coronary Computed Tomography Angiography: A Cross-Sectional Study

Tetsuo Hirata et al. J Cardiovasc Dev Dis. .

Abstract

Liver fibrosis scores, indicative of hepatic scarring, have recently been linked to coronary artery disease (CAD). We investigated the association between CAD and the fibrosis-4 index (FIB-4I) in patients who underwent coronary computed tomography angiography (CCTA). This study included 1244 patients who were clinically suspected of having CAD. The presence or absence of CAD was the primary endpoint. FIB-4I was higher in the CAD group than in the non-CAD group (1.95 ± 1.21 versus [vs.] 1.65 ± 1.22, p < 0.001). FIB-4I was also higher in the hypertension (HTN) group than in the non-HTN group (1.90 ± 1.32 vs. 1.60 ± 0.98, p < 0.001). In all patients, high FIB-4I (≥2.67) was a predictor of presence of CAD (odds ratio [OR]: 1.92, 95% confidence interval [CI]: 1.30-2.83, p = 0.001), and low FIB-4I (≤1.29) was proven to be a predictor of absence of CAD (OR: 0.65, 95% CI: 0.48-0.88, p = 0.006). In the HTN group, high and low FIB-4I levels, were found to be predictors for CAD (OR: 2.01, 95% CI: 1.26-3.21, p < 0.001 and OR: 0.65, 95% CI: 0.45-0.94, p < 0.022, respectively), in particular. FIB-4I may serve as a diagnostic indicator of the presence or absence of CAD in hypertensive patients undergoing CCTA.

Keywords: coronary artery disease; coronary computed tomography angiography; fibrosis-4 index; hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Comparative evaluation of FIB-4I values between the four groups. * p < 0.05, ** p < 0.01, and *** p < 0.001, according to the Kruskal-Wallis and Steel-Dwass tests. Group 1, HTN and CAD; Group 2, HTN without CAD; Group 3, without HTN with CAD; Group 4, without HTN and CAD; NS, not significant; CAD, coronary artery disease; HTN, hypertension; FIB-4I, fibrosis-4 index.
Figure 2
Figure 2
Comparative evaluation of the prevalence of CAD between the three groups. *** p < 0.001. Low FIB-4I, ≤1.29; intermediate FIB-4I, 1.30–2.66; high FIB-4I, ≥2.67; CAD, coronary artery disease; FIB-4I, fibrosis-4 index.
Figure 3
Figure 3
Comparative evaluation of the Gensini score between the three groups. ** p < 0.01 and *** p < 0.001 according to the Kruskal-Wallis and Steel-Dwass tests. CAD, coronary artery disease; FIB-4I, fibrosis-4 index.
Figure 4
Figure 4
Representative coronary computed tomography angiography images. (a) A 66-year-old man with no noticeable CAD, a FIB-4I level of 0.85, and a Gensini score of 0; and (b) A 78-year-old woman with a FIB-4I level of 3.13 and a Gensini score of 45, showing multiple coronary artery stenoses. CAD, coronary artery disease; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery.

References

    1. Ghattas A., Griffiths H.R., Devitt A., Lip G.Y., Shantsila E. Monocytes in coronary artery disease and atherosclerosis: Where are we now? J. Am. Coll. Cardiol. 2013;62:1541–1551. doi: 10.1016/j.jacc.2013.07.043. - DOI - PubMed
    1. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C., Prescott E., Storey R.F., Deaton C., Cuisset T., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2020;41:407–477. doi: 10.1093/eurheartj/ehz425. - DOI - PubMed
    1. Jansen S.A., Huiskens B., Trompet S., Jukema J., Mooijaart S.P., Willems van Dijk K., van Heemst D., Noordam R. Classical risk factors for primary coronary artery disease from an aging perspective through Mendelian Randomization. Geroscience. 2022;44:1703–1713. doi: 10.1007/s11357-021-00498-9. - DOI - PMC - PubMed
    1. Khandia R., Puranik N., Lodhi N., Gautam B., Alqahtani T., Alqahtani A.M., Alamri A.H., Chidambaram K. Comparing heart risk scores to identify the most important risk factors for cardiovascular diseases. Eur. Rev. Med. Pharmacol. Sci. 2021;25:7947–7963. doi: 10.26355/eurrev_202112_27645. - DOI - PubMed
    1. Marušić M., Paić M., Knobloch M., Liberati Pršo A.M. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can. J. Gastroenterol. Hepatol. 2021;2021:6613827. doi: 10.1155/2021/6613827. - DOI - PMC - PubMed

LinkOut - more resources